Get access

Development of selected reaction monitoring-MS methodology to measure peptide biomarkers in prostate cancer

Authors

  • Anastasia K. Yocum,

    1. Michigan Center for Translational Pathology, Ann Arbor, MI, USA
    2. Department of Pathology, University of Michigan, Ann Arbor, MI, USA
    3. Department of Urology, University of Michigan, Ann Arbor, MI, USA
    Search for more papers by this author
  • Amjad P. Khan,

    1. Michigan Center for Translational Pathology, Ann Arbor, MI, USA
    Search for more papers by this author
  • Rong Zhao,

    1. Michigan Center for Translational Pathology, Ann Arbor, MI, USA
    Search for more papers by this author
  • Arul M. Chinnaiyan

    Corresponding author
    1. Michigan Center for Translational Pathology, Ann Arbor, MI, USA
    2. Department of Pathology, University of Michigan, Ann Arbor, MI, USA
    3. Howard Hughes Medical Institute, University of Michigan Medical School, Ann Arbor, MI, USA
    4. Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA
    • Investigator, Howard Hughes Medical Institute, Department of Pathology and Urology, University of Michigan Medical School, 1400 E. Medical Center Drive, 5316 UMCCC, Ann Arbor, MI 48109, USA Fax: +1-734-615-4498
    Search for more papers by this author

Abstract

Prostate cancer is a leading cause of cancer-related death. The current modality of diagnosis, the measurement of serum PSA, not only suffers from lack of specificity, but does not distinguish clinical cases in which current treatment measures would be most successful, i.e. aggressive, life-threatening tumors. A multiplexed MS methodology, selected reaction monitoring-MS/MS coupled with stable isotope dilution (SID), was developed and tested in both cells lines and clinical tissue samples. Standard curves were generated for two peptides representing PSA and one peptide from each of two additional orthogonally validated biomarkers, AMACR and EZH2. The standard curves show high reproducibility, sensitivity, and good linearity. All four peptides were then measured in six clinically relevant cell lines and are in agreement with the biochemical characteristics of each individual cell line. The SID selected reaction monitoring-MS/MS methodology was then transferred to tissue samples, in which the assay shows potential to differentiate benign disease from localized cancer and localized cancer from aggressive metastatic disease. These results establish the preliminary development of a rational targeted MS platform that strives to bridge the gap between discovery and validation of biomarkers for the detection of prostate cancer.

Get access to the full text of this article

Ancillary